Financial Performance - As of April 30, 2023, the company's cash and cash equivalents totaled approximately $68 million, down from approximately $85.4 million as of April 30, 2022, indicating a decrease of about 20.3%[390] - Total operating expenses for the year ended April 30, 2023, were $6,455,494, an increase of $2,063,480 or approximately 47.5% compared to the previous year[401] - Loss from operations for the year ended April 30, 2023, was $6,455,494, reflecting an increase of $2,063,480 or about 47.5% from the year ended April 30, 2022[403] - Other income for the year ended April 30, 2023, was $2,139,501, compared to $152,853 in the previous year, representing a significant increase attributed mainly to interest income[404] - The company had no revenues for the fiscal years ended April 30, 2023, and 2022[400] - The company reported a net cash used in operating activities of $(3,793,731) for the year ended April 30, 2023, compared to $(4,117,319) for the year ended April 30, 2022, showing an improvement[406] Share Structure - The company completed a 1:1500 reverse stock split effective July 12, 2021, reducing the authorized number of shares from 50 billion to 33,333,334[384] - On March 14, 2023, the company increased the number of authorized shares to 133,333,334 shares[385] Research and Development - The company is preparing for a clinical trial in LAPC using encapsulated live cells, following a clinical hold placed by the FDA on its IND submission[378][379] - The company is developing a potential therapy for Type 1 diabetes using encapsulated genetically modified insulin-producing cells, aimed at functioning as a bio-artificial pancreas[382] Cash Flow Activities - Cash used in operating activities for the year ended April 30, 2023, was primarily due to net losses, offset by securities issued for services and changes in prepaid expenses, accounts payable, and accrued expenses[407] - No investing activities were reported for the years ended April 30, 2023, and 2022[408] - Cash used in financing activities for the year ended April 30, 2023, was mainly attributable to Repurchase Programs, while cash provided in 2022 was primarily from proceeds of the First and Second 2021 Offerings[409] Accounting Policies - The company follows U.S. GAAP for its consolidated financial statements, requiring management to make assumptions and estimates that could materially affect reported financial results[410] - Research and Development (R&D) expenses are expensed as incurred, including costs for acquiring technologies with no alternative future use[412] - Stock-based compensation is measured and recognized according to ASC 718, impacting the compensation expense for stock-based awards made to employees[413] - Basic net income (loss) per share is calculated using the weighted-average number of shares outstanding, with potentially dilutive stock options excluded from the diluted calculation due to anti-dilutive effects[414] - No new accounting pronouncements were disclosed in the company's consolidated financial statements for the current and prior year[415] - The company is classified as a smaller reporting company and is not required to provide additional market risk disclosures[416]

Product Development - The company is focused on developing cellular therapies for cancer, diabetes, and malignant ascites using its proprietary "Cell-in-a-Box" technology[140] - The current product candidate is referred to as "CypCaps™" and is intended for use in various cancer therapies, including LAPC[140] - The company is developing therapies for Type 1 diabetes using encapsulated genetically modified insulin-producing cells[144] - The encapsulation technology has shown potential in laboratory settings to create a micro-environment for cell survival and production of active molecules[141] - The company is also exploring therapies for malignant ascites using the same encapsulated cells employed for pancreatic cancer[143] Regulatory Challenges - Due to a clinical hold placed by the FDA on the IND for LAPC, the company is facing delays and increased costs in its development efforts[135] - The FDA has requested additional data and studies to lift the clinical hold, including genetic stability studies and compatibility assessments of delivery devices[149] - The company is conducting various studies requested by the FDA, including biocompatibility studies and stability studies for its product candidate for pancreatic cancer[154] - The company has retained Biologics Consulting for regulatory expertise and gap analysis to assist with IND resubmission[153] Financial Performance - The company reported no revenues for the three and nine months ended January 31, 2023, and 2022[159] - Total operating expenses for the three months ended January 31, 2023, increased by $696,864 to $1,552,983 from $856,119 in the same period of 2022[160] - Research and Development (R&D) expenses decreased by 71% to $45,393 for the three months ended January 31, 2023, compared to $158,039 in 2022[161] - Director fees increased by 838% to $795,969 for the three months ended January 31, 2023, from $84,897 in the same period of 2022[161] - Other income, net, for the three months ended January 31, 2023, was $788,847, compared to other expense, net of $44,829 for the same period in 2022[164] - Interest income for the nine months ended January 31, 2023, was $1,214,562, up from $71,078 in the same period of 2022[165] - Total operating expenses for the nine months ended January 31, 2023, increased by $2,667,898 to $5,552,211 from $2,884,313 in the same period of 2022[160] - General and administrative, legal, and professional expenses increased by 125% to $3,238,824 for the nine months ended January 31, 2023, compared to $1,437,324 in 2022[163] Cash Flow and Liquidity - Net cash used in operating activities for the nine months ended January 31, 2023, was approximately $3.5 million, compared to $2.9 million for the same period in 2022[167] - Cash and cash equivalents as of January 31, 2023, totaled approximately $73 million, down from approximately $87 million as of January 31, 2022[172] - The company reported a net cash used in financing activities of approximately $9.3 million, primarily due to the repurchase of common stock[171] - The increase in operating expenses was approximately $3.5 million, contributing to the decrease in cash[172] - The company had no investing activities for the nine months ended January 31, 2023, and 2022[170] - The company expects to use existing cash balances and may consider additional debt or equity issuances to meet liquidity needs[179] - Total estimated cost for service agreements related to clinical hold is approximately $214,000, with $157,000 attributed to related parties[180] - The company received gross proceeds of approximately $70 million from a registered direct offering and concurrent private placement in August 2021[175] - The company reported a net increase (decrease) in cash and cash equivalents of approximately $(12.76) million for the nine months ended January 31, 2023[172] - The company has a history of operating losses, which may affect its ability to raise capital on acceptable terms[179] Strategic Initiatives - The company has entered into a Cooperation Agreement with Iroquois Master Fund Ltd. to reconstitute its Board and evaluate its business strategy[140] - The company has curtailed spending on its development programs pending the completion of a review by the Business Review Committee[147] - The company is not currently allocating resources to its Cannabis Program until it receives FDA approval for its LAPC clinical trial[145]

Product Development - The company is focused on developing cellular therapies for cancer, diabetes, and malignant ascites using its proprietary "Cell-in-a-Box" technology[135]. - The current product candidate is referred to as "CypCaps™" and is intended for use in therapies for several types of cancer, including LAPC[135]. - The company is currently conducting a pilot study involving two pigs to evaluate the safety and activity of its product candidate for pancreatic cancer[145]. - The encapsulation technology aims to protect genetically engineered live human cells, enhancing their survival and efficacy in producing active molecules[136]. - The company is also developing therapies for Type 1 diabetes using encapsulated genetically modified insulin-producing cells[139]. Regulatory Challenges - Due to a clinical hold placed by the FDA on the IND for LAPC, the company is facing delays and increased costs in its development efforts[131]. - The FDA has requested additional data and studies to lift the clinical hold, including genetic stability studies and a biocompatibility assessment[144]. - The company is currently addressing various regulatory requirements to lift the clinical hold on its IND for the planned clinical trial in LAPC[152]. Financial Performance - The total operating expenses for the three months ended October 31, 2022, increased by $1,313,777 to $2,318,620 from $1,004,843 in the same period in 2021, primarily due to increases in R&D costs, compensation, legal, and consulting expenses[155]. - R&D expenses for the three months ended October 31, 2022, were $177,996, reflecting a 32% increase from $135,220 in the same period in 2021[156]. - Compensation expenses for the three months ended October 31, 2022, were $400,420, a 51% increase from $265,012 in the same period in 2021[156]. - The total operating expenses for the six months ended October 31, 2022, increased by $1,971,034 to $3,999,228 from $2,028,194 in the same period in 2021[157]. - R&D expenses for the six months ended October 31, 2022, were $337,269, a 21% increase from $278,833 in the same period in 2021[158]. - Compensation expenses for the six months ended October 31, 2022, were $728,138, a 36% increase from $533,897 in the same period in 2021[158]. - General and administrative, legal, and professional expenses for the three months ended October 31, 2022, were $1,637,869, representing a 201% increase from $543,557 in the same period in 2021[156]. - General and administrative, legal, and professional expenses for the six months ended October 31, 2022, were $2,778,759, a 155% increase from $1,091,251 in the same period in 2021[158]. - The company had no revenues for the three and six months ended October 31, 2022, and 2021[154]. Cash Flow and Liquidity - Net cash used in operating activities for the six months ended October 31, 2022, was $(2,963,642), compared to $(2,626,834) for the same period in 2021, indicating an increase in operational losses[162]. - Cash and cash equivalents as of October 31, 2022, totaled approximately $77 million, down from approximately $87 million as of October 31, 2021, primarily due to increased operating expenses and stock repurchase[165]. - The cash used in financing activities for the six months ended October 31, 2022, was approximately $(5.5 million) due to the repurchase of common stock[164]. - The company expects to use existing cash balances and may consider additional debt or equity issuances to meet liquidity needs, given the history of operating losses[171]. - The total cost of service agreements related to the clinical hold on the IND submission involving LAPC is estimated to be approximately $347,000, with a significant portion allocated to related parties[172]. - The company had no investing activities for the six months ended October 31, 2022, and 2021, indicating a focus on operational rather than investment expenditures[163]. - The company received gross proceeds of approximately $70 million from the Second Offering in August 2021, contributing to its capital resources[168]. - The company reported a net increase (decrease) in cash and cash equivalents of $(8,438,069) for the six months ended October 31, 2022, compared to an increase of $84,736,506 in the same period of 2021[162]. - The company has no off-balance sheet arrangements that could materially affect its financial condition, revenues, or expenses[170]. Corporate Governance - The company has entered into a Cooperation Agreement with Iroquois Master Fund Ltd. to reconstitute its Board and evaluate its business strategy[135]. - Spending on development programs has been curtailed pending the completion of the Business Review Committee's evaluation[142]. - The company is exploring new frameworks for its relationship with SG Austria, which may impact its development programs[135].

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2022 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission file number 001-40699 PHARMACYTE BIOTECH, INC. (Exact name of registrant as specified in its charter) (State or othe ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended April 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number 001-40699 PHARMACYTE BIOTECH, INC. (Exact name of registrant as specified in its charter) Nevada 62- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Nevada 62-1772151 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 3960 Howard Hughes Parkw ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 31, 2021 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission file number 001-40699 PHARMACYTE BIOTECH, INC. (Exact name of registrant as specified in its charter) (State or o ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2021 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission file number 001-40699 PHARMACYTE BIOTECH, INC. (Exact name of registrant as specified in its charter) Nevada 62-1772 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended April 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number 001-40699 PHARMACYTE BIOTECH, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2021 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission file number 333-68008 PHARMACYTE BIOTECH, INC. (Exact name of registrant as specified in its charter) Nevada 62-1772151 (State or o ...